Legal Liabilities Weigh Heavily on Bayer’s Financial Outlook

Bayer’s recently published annual report for 2025 delivers an unambiguous message: the legal risks associated with glyphosate continue to overshadow the company, and their financial impact is now becoming starkly visible in its cash flow statements. Increased provisions, a negative free cash flow forecast for 2026, and ongoing uncertainty around a proposed U.S. settlement are creating fresh concerns. The central question remains whether the conglomerate can finally contain this protracted legal battle.

Cash Flow Under Pressure as Provisions Swell

The annual report reveals a significant increase in provisions for legal disputes, now standing at 11.8 billion euros. The vast majority of this sum, 9.6 billion euros, is allocated specifically for glyphosate litigation. This move underscores that the legacy issue is no longer merely a risk to reputation or a source of potential court losses; it has solidified into a substantial financial burden.

The forward-looking view is even more concrete. Management anticipates a negative free cash flow for 2026. Bayer identifies litigation-related payments of approximately 5 billion euros as the primary driver. To manage these outflows, the company has secured bridge financing of 8 billion U.S. dollars. The subsequent strategy involves refinancing this through the issuance of senior bonds and hybrid securities.

A Major Settlement Proposal Awaits Judicial Scrutiny

At the heart of the matter is a proposed U.S. settlement worth up to 7.25 billion U.S. dollars. According to the company, this agreement is designed to resolve approximately 65,000 Roundup claims over a period of 21 years, covering both current and future cases. A critical hurdle remains, however: the presiding judge, Timothy Boyer of the St. Louis City Circuit Court, has not yet scheduled a hearing to review the proposal.

Furthermore, the plan faces opposition from some plaintiff attorneys. Several law firms are calling for a delay of at least 60 days and are raising fundamental questions about the settlement’s fairness. In essence, while the financial figure is on the table, the timeline for resolution is entirely uncertain.

Should investors sell immediately? Or is it worth buying Bayer?

Concurrently, Bayer is pursuing a separate legal strategy. On March 2, the company submitted a brief to the Supreme Court in the case of Durnell v. Monsanto. Bayer’s argument centers on federal law preempting state-level warning requirements. The proceedings will gain relevance on April 27, when oral arguments are scheduled to determine whether certain “failure-to-warn” claims are precluded by federal statute. Analysts from JPMorgan estimate that such cases represent roughly 80% of the filed lawsuits.

Share Performance Reflects Mounting Concerns

The market has reacted poorly to the combination of heightened provisions and impending cash flow strain. The share price closed at 37.70 euros on Tuesday. Over the past 7 days, the stock has declined by 11.29%, and its 30-day performance shows a loss of 16.23%. A broader perspective reveals the stock’s volatility: it maintains a 12-month gain of 58.07%, yet it currently trades 23.33% below its 52-week high of 49.17 euros.

The short-term technical picture is also notable. With a Relative Strength Index (RSI) reading of 19.6, the shares appear deeply oversold. This technical condition, however, does not offset the fundamental pressure from the recent news flow.

The calendar now points to two pivotal legal events. All eyes will be on the Supreme Court hearing scheduled for April 27. Meanwhile, the proposed $7.25 billion settlement still lacks a definitive court date. The outcomes of these two legal milestones will likely determine whether the increased provisions and anticipated 2026 cash outflow can be managed predictably, or if the weight of litigation will continue to hamper the company’s equity performance.